What is HC Wainwright’s Forecast for PVLA FY2024 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – HC Wainwright issued their FY2024 earnings estimates for Palvella Therapeutics in a research report issued on Thursday, December 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($4.37) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $12.00 on Monday. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32. The firm has a market cap of $15.84 million, a P/E ratio of -0.99 and a beta of 0.61.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.39% of the stock is owned by company insiders.